JANX News and Press, Janux Therapeutics Inc. From 04/25/24

2024-04-25 18:33:59 ET Summary CytomX Therapeutics is a biotech company developing anticancer therapeutics using a technology that activates an immune response within the tumor microenvironment. Their main pipeline candidate, CX-904, is a bispecific "probody" targeting EGFR and CD...

2024-04-17 13:12:56 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Generally, the idea of selling securities rankles the public’s nerve, yet trimming overbought stocks is just as important a discipline as knowing what to buy. It might be even more impor...

2024-04-16 18:25:52 ET Summary Lyell Immunopharma, Inc.'s stock price has risen over 20% YTD and over 45% in the past 12 months. The company focuses on T-cell therapies for solid tumors and has two clinical-stage assets. Lyell has upcoming data catalysts, with Phase 1 results ...

2024-04-16 14:25:11 ET Jones Trading has initiated Janux Therapeutics ( NASDAQ: JANX ) at buy citing the promise behind the technology of the company's two lead programs, both in phase 1 for various solid tumors.... Read the full article on Seeking Alpha For further deta...

2024-04-12 05:40:00 ET Janux Therapeutics (NASDAQ: JANX) stock is crushing it. The stock was up 42.4% for the week as of market close on Thursday, according to data from S&P Global Market Intelligence . The big gain came after Bloomberg reported on Wednesday that Janux w...

2024-04-11 09:00:00 ET Summary Janux Therapeutics' JANX007 shows promising Phase 1 data in treating advanced prostate cancer, with significant PSA level reductions. Early data suggest JANX007 could meet unmet needs in mCRPC treatment, with potential for dose optimization and safet...

2024-04-10 18:39:00 ET Clinical-stage biotech Janux Therapeutics (NASDAQ: JANX) was a standout title on a gloomy Wednesday stock market. As investors fretted about an unfavorable inflation report from the federal government, bulls piled into the company's shares on a report that it ...

2024-04-10 13:48:32 ET More on Janux Therapeutics Janux Therapeutics: Yes There's New Data; No It's Not A Buy Here Trial Data Triggers Massive Rally In Janux Therapeutics Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024 Cantor ...

2024-03-23 17:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-20 12:21:57 ET More on Janux Therapeutics Janux Therapeutics: Yes There's New Data; No It's Not A Buy Here Trial Data Triggers Massive Rally In Janux Therapeutics Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024 Janux T...